| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA432: Everolimus for advanced renal cell carcinoma after previous treatment (replaced TA219) |
|
Medicine details |
|
| Medicine name | everolimus (Afinitor®) |
| Formulation | tablet |
| Reference number | 141 |
| Indication | Treatment of patients with advanced renal cell carcinoma, whose disease has progressed on or after treatment with VEGF-targeted therapy |
| Company | Novartis Pharmaceuticals UK Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 23/09/2009 |
| NICE guidance | TA432: Everolimus for advanced renal cell carcinoma after previous treatment (replaced TA219) |